Videos

Plasma donation

The Power of Plasma Donation

From the PPTA Global Board of Directors: "Thank you, plasma donors!"

From PPTA:
"Thank you, plasma donors!"

Spotlight on Plasma Part One:
Together We Are Stronger

The Gift of Life

Becoming a Plasma Donor

Plasma Protein Therapies

Doctors Praise Plasma Protein Therapies

Saving and Improving Lives
Celebrating PPTA's 20th Aniversary

PPTA Webinars

Plasma 101

PPTA webinar on unique patient access challenges to plasma-derived medicinal products in COVID times

PPTA Podcasts

Plasma is Life podcast series episode 2:
U.S. Election 2020 Wrap-Up

Plasma is Life podcast series episode 1:
Dr. Karen Etchberger, CSL Behring

Global Plasma Summit

Welcome to the Global Plasma Summit

Combating COVID-19 Industry Spotlight: CoVIg-19 Plasma Alliance

Plasma: An Overview

Combating COVID-19 Industry Spotlight: Emergent

Combating COVID-19 Industry Spotlight: Grifols

Experts on Coronavirus: The Virus, The Disease, Prevention and Treatment

Patient Perspectives on COVID-19
and Access to Care

Combating COVID-19 Industry Spotlight: Kedrion

Keynote Address – Stella Kyriakides, European Commissioner for Health and Food Safety

Keynote Address – Admiral Brett Giroir, MD, U.S. Department of Health & Human Services Assistant Secretary for Health

Media and Information

PPTA News

Yes, you can donate source plasma after getting the COVID vaccine +

Recently, news outlets have suggested that people are not allowed to donate source plasma if they have received either of the two experimental COVID-19 vaccines currently available in the U.S. This is incorrect. Current guidance from the U.S. Food and Drug Administration (FDA) recommends that those who have received one of the available vaccines should not donate convalescent plasma. Healthy and eligible people who have received the COVID-19 vaccine are still encouraged to donate regular source plasma for further manufacture into plasma-derived therapies.
Read More
Treatments for rare diseases at risk, due to the decline of plasma donations +

Representatives of patient advocacy groups, expert physicians, thought leaders, and representatives from the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research came together on December 9 at a roundtable sponsored by the Plasma Protein Therapeutics Association (PPTA) to discuss the impacts on people with rare diseases if not enough plasma is available to manufacture lifesaving plasma-derived therapies. These therapies are often the only treatments available for people with primary immune deficiencies, bleeding disorders, Alpha-1 Antitrypsin deficiency, hereditary angioedema, and certain neurological conditions.
Read More
Inception Impact Assessment Underlines the Need for Timely Action to Decrease the Reliance on Third Countries for Plasma +

The Plasma Protein Therapeutics Association (PPTA) welcomes the European Commission’s publication of the Inception Impact Assessment (IIA) as a necessary step in the ongoing evaluation of the EU legislation on blood, tissues, and cells (BTC). Rightfully, the assessment underlines the need for timely action to decrease Europe’s reliance on third countries for plasma. We appeal to authorities to urgently take the necessary steps to collect more plasma through plasmapheresis in Europe As highlighted by the European Commission, plasmapheresis is a more efficient collection method compared to the collection of recovered plasma.¹
Read More
PPTA Statement on the Urgent Need for Plasma Donation +

COVID-19 continues to present a prolonged, global public health emergency, but PPTA remains steadfastly committed to its mission to promote the availability of — and access to — safe and effective plasma protein therapies for all patients. PPTA member companies operate more than 1,000 Source plasma donation centers in the U.S. and four countries in the European Union and manufacture plasma-derived therapies that treat patients with serious, rare, and often genetic diseases and disorders, including: primary immune deficiencies, bleeding disorders, Alpha-1 Antitrypsin deficiency, hereditary angioedema, and certain neurological conditions. These conditions are often only treated with therapies produced from plasma.
Read More

1
2
3

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap